Udit Batra is Chief Executive Officer of MilliporeSigma
, the €6.2 billion Life Science business of Merck KGaA, Darmstadt, Germany and a member of its Executive Board — the first American to hold this position in the company’s 350-year history. In addition to leading MilliporeSigma, Udit has Board responsibility for the company’s global Information Technology function and oversees Merck KGaA, Darmstadt, Germany’s Bioethics Advisory Panel.
Born in New Delhi, India, Udit is an accomplished executive who has dedicated his career to improving health for people globally, bringing more than 20 years’ experience in healthcare and the life sciences. After Udit became CEO in 2014, he and his team developed and executed a growth strategy that included the 2015 acquisition of chemicals and technology giant, Sigma-Aldrich. Udit architected and led this merger — the largest acquisition in the history of Merck KGaA, Darmstadt, Germany and one of the largest ever in the life science industry.
Today, Udit continues to lead the business through a strategic transformation that has made MilliporeSigma a top-three player in the industry and an employer of choice in many regions where it operates around the world.
MilliporeSigma, with a Life Science Center in Burlington, Massachusetts, was named to The Boston Globe's annual "Top Places to Work" list in 2016 and 2017 and received an exclusive certification as a top employer in North America by the independent Top Employers Institute in 2018 for the second year in a row. In 2019, MilliporeSigma was named to the Boston Business Journal’s Best Places to Work award. Also under Udit’s leadership, MilliporeSigma has earned several prestigious awards for innovation, including the R&D 100 Award
for Top Innovations in 2016; a Life Science Industry Award by BioInformatics in 2016 and an R&D 100 Award
for Corporate Responsibility in 2017.
Udit has earned a well-deserved reputation for driving business growth and turnarounds, as well as building high-performing teams. Previously, as head of the company’s global Consumer Health business, he and his team more than doubled the profitability of the business, making it the fastest-growing sector within Merck KGaA, Darmstadt, Germany.
Prior to Merck KGaA, Darmstadt, Germany, Udit served in a range of leadership positions at Novartis, a Swiss multinational pharmaceutical company. In addition to leading Corporate Strategy and Global Public Health and Market Access for Vaccines and Diagnostics, he also served as president of the Australia Pharma business. During his tenure, this subsidiary became the fastest-growing business within Novartis. Earlier in his career, Udit held senior positions in the healthcare, consumer and non-profit practices at McKinsey & Company, a global strategy and consulting company.
Udit earned both a Ph.D. and BS in chemical engineering from Princeton University and the University of Delaware, respectively. He started his career as a research engineer fellow at Merck & Co., Inc., Kenilworth, NJ, where he worked on vaccines and small molecules. He has received multiple honors and awards, including nationally competitive, recognized fellowships at Merck & Co., Inc., Kenilworth, NJ; DuPont; and Mitsubishi. He serves on the boards of the Greater Boston Chamber of Commerce and the Massachusetts High Technology Council, as vice chairman; he is also a member of the Advisory Council at Princeton University’s Department of Chemical Engineering.
Udit was named "CEO of the Year" by CPhI Pharma
in 2016 and was also recognized for his strategic leadership by PharmaVOICE 100
in its list of top influencers for 2016. In 2018, he was awarded the MassBioEd Foundation’s Champions for Biotechnology award. Udit is a frequent keynote speaker, representing the company at global investor conferences and industry congresses. Most recently, he addressed the National Institute for Innovation in Manufacturing Biopharmaceuticals in Washington, DC; BioAsia in India; Societe de Chimie; University of Delaware — Gerster Lecture; and the Drug, Chemical and Associated Technologies Association, among others.